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the respective values of 0.39 versus 0.51 mg/dL, although
statistically different, are not clinically different.
It should be clearly noted that our study was not performed
to demonstrate the efficacy of aprotinin in pediatric patients.
There have been numerous previous studies to indicate that
aprotinin is indeed efficacious in pediatric patients undergoing
CPB. A recent meta-analysis by Arnold and colleagues20 re-
ported that aprotinin reduced the proportion of children who
received red blood cell or whole blood transfusions during
cardiac surgery by 33%. Our own study published in 2003
demonstrated that with the use of aprotinin, children were
exposed to 3 instead of 5 red blood cell units. Operative closure
time was less (ie, 93 vs 127 minutes, a savings of 34 minutes).
The Ann Arbor group in 1996 reported in a prospective,
randomized, placebo-controlled, double-blind trial that aproti-
nin resulted in fewer exposures to bank-blood components and
was also associated with a savings in the patient charges for
blood components, operating room time, and duration of hos-
pitalization.8 The group from Eggleston Children’s Hospital in
1998 reported similar findings.9
A recent study at the University of California, San Fran-
cisco, evaluated the use or nonuse of aprotinin in patients
undergoing the Norwood, Glenn, and Fontan procedures.
The authors concluded the following: “The key point of
these data is that we did not see evidence of clinical concern
in this population of children with . . . aprotinin. If anything
our data support the safety of these drugs for use in children
undergoing the repair of congenital cardiac defects.”21 The
Milwaukee group, in particular, has demonstrated the utility
and safety of aprotinin use and reuse in pediatric patients
undergoing cardiothoracic procedures.22,23 They concluded
that the risk of hypersensitivity reactions to aprotinin is low
(approximately 1%), even with multiple exposures to the
medication. Our analysis of the risk of re-exposure confirms
the Milwaukee analysis; we had no adverse responses in 94
patients re-exposed within 1 year.
In our study of 2090 pediatric patients undergoing CPB,
there was no association between the use of high-dose aproti-
nin and operative or late mortality, biochemical acute kidney
failure, need for temporary dialysis, or neurologic complica-
tions. Given the previous studies demonstrating its efficacy, we
continue to use aprotinin in all pediatric patients undergoing
CPB.
References
1. Approval of aprotinin [press release]. Washington (DC): US Food and
Drug Administration; December 30, 1993. Available at: http://www.
fda.gov/bbs/topics/NEWS/NEW00453.html.
2. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, double-blind,
placebo-controlled trial of aprotinin for reducing blood loss and the
requirement for donor-blood transfusion in patients undergoing repeat
coronary artery bypass grafting. Circulation. 1995;92:2236-44.
3. Cosgrove DM 3rd, Heric B, Lytle BW, et al. Aprotinin therapy for
reoperative myocardial revascularization: a placebo-controlled study.
Ann Thorac Surg. 1992;54:1031-6.
4. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on
clinical outcomes in coronary artery bypass graft surgery: a systematic
review and meta-analysis of randomized clinical trials. J Thorac
Cardiovasc Surg. 2004;128:442-8.
5. Kozik DJ, Tweddell JS. Characterizing the inflammatory response to
cardiopulmonary bypass in children. Ann Thorac Surg. 2006;
81(suppl):S2347-54.
6. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA. Apro-
tinin and methylprednisolone equally blunt cardiopulmonary bypass-
induced inflammation in humans. J Thorac Cardiovasc Surg. 1995;
110:1658-62.
7. Costello JM, Backer CL, de Hoyos A, Binns HJ, Mavroudis C.
Aprotinin reduces operative closure time and blood product use after
pediatric bypass. Ann Thorac Surg. 2003;75:1261-6.
8. D’Errico CC, Shayevitz JR, Martindale SJ, Mosca RS, Bove EL. The
efficacy and cost of aprotinin in children undergoing reoperative open
heart surgery. Anesth Analg. 1996;83:1193-9.
9. Miller BE, Tosone SR, Tam VK, et al. Hematologic and economic
impact of aprotinin in reoperative pediatric cardiac operations. Ann
Thorac Surg. 1998;66:535-40.
10. Mangano DT, Tudor IC, Dietzel C, Multicenter Study of Perioperative
Ischemia Research Group, Ischemia Research and Education Founda-
tion. The risk associated with aprotinin in cardiac surgery. N Engl
J Med. 2006;354:353-65.
11. Mangano DT, Miao Y, Vuylstekc A, et al. Mortality associated with
aprotinin during 5 years following coronary artery bypass graft sur-
gery. JAMA. 2007;297:471-9.
12. Levy JH, Ramsay JG, Guyton RA. Aprotinin in cardiac surgery [letter
to the editor]. N Engl J Med. 2006;354:1953-7.
13. Royston D, van Haaften N, De Vooght P. Aprotinin; friend or foe? Eur
J Anesthesiol. 2007;24:6-14.
14. Ferguson TB Jr. Aprotinin—are there lessons learned? JAMA. 2007;
297:471-9.
15. Jacobs JP, Mavroudis C, Jacobs ML, Joint EACTS-STS Congenital
Database Committee. What is operative mortality? Defining death in a
surgical registry database: a report of the STS Congenital Database
Taskforce and the Joint EACTS-STS Congenital Database Committee.
Ann Thorac Surg. 2006;81:1937-41.
16. Kincaid EH, Ashburn DA, Hoyle JR, Reichert MG, Hammon JW, Kon
ND. Does the combination of aprotinin and angiotensin-converting
enzyme inhibitor cause renal failure after cardiac surgery? Ann Thorac
Surg. 2005;80:1388-93.
17. Therneau TM, Grambsch PM. Modeling survival data: extending the
Cox model. New York: Springer; 2000.
18. Liang KY, Zeger SL. Longitudinal data analysis using generalized
linear models. Biometrika. 1986;73:13-22.
19. O’Brien SM, Clarke DP, Jacobs JP, et al. Accuracy of the Aristotle
basic complexity score for classifying the mortality and morbidity
potential of congenital heart surgery procedures. Paper presented at:
43rd Annual Meeting of the Society of Thoracic Surgeons; January 29,
2007; San Diego, Calif.
20. Arnold DM, Fergusson DA, Chan AK, et al. Avoiding transfusions in
children undergoing cardiac surgery: a meta-analysis of randomized
trials of Aprotinin. Anesth Analg. 2006;102:731-7.
21. Skidmore KL, Azakie A. Aprotinin and Sevoflurane do not affect renal
function during single-ventricle palliative surgery [letter to the editor].
Anesth Analg. 2006;103:1614-5.
22. Jaquiss RD, Chanayem NS, Zacharisen MC, et al. Safety of aprotinin
use and re-use in pediatric cardiothoracic surgery. Circulation. 2002;
106(suppl I):I90-4.
23. Tweddell JS, Berger S, Frommelt PC, et al. Aprotinin improves
outcome of single-ventricle palliation. Ann Thorac Surg. 1996;62:
1329-36.
Discussion
Dr James S. Tweddell (Milwaukee, Wis). That was an excellent
presentation, Carl, as usual. This is a timely contribution from the
group at Children’s Memorial Hospital. The authors looked at their
entire experience with aprotinin, a period of 6 years, and compared
this with the previous 6-year period. Just over 2000 patients are
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included, pretty much evenly divided between the use and nonuse
of aprotinin, making this the largest single-center report concern-
ing aprotinin use in pediatrics by far.
Despite an increase in case complexity in the most recent
aprotinin cohort, there is no difference in mortality or renal im-
pairment, suggesting that aprotinin use is safe in this age group.
Incidentally, our aprotinin use policy is identical to yours.
The limitations of this study have been acknowledged by the
authors and most importantly include the comparison of noncon-
temporary patient groups. I would contend that this is a form of
selection bias.
This study begins in 1994, and just for some perspective, in
1994, the sitcom “Friends” premiered on NBC, Netscape 1.0 was
released, and George Bush was unequivocally elected governor of
Texas. Times have changed.
Since 1994, we have seen some important changes in various
aspects of preoperative, intraoperative, and postoperative manage-
ment of patients with congential heart disease, including some
pioneered from your institution.
Taking the devil’s advocate position, one could argue that your
most recent results, which are excellent, would have been even
better if you had not used aprotinin. Therefore my comments and
questions are really directed at potential ways around this time–
bias issue.
The most recent studies from the Ischemia Research and Edu-
cation Foundation purported to show that aprotinin use was asso-
ciated with a significantly increased risk of complications in
adults—myocardial infarction, stroke and renal failure—in pa-
tients not having complex operations. Could you or did you
analyze the effect of aprotinin risk within risk stratification cate-
gories? You could divide your patient population above and below
the 50th percentile Aristotle score, for example, and this would be
a way to match aprotinin use and risk stratification. Perhaps the
risk/benefit ratio of aprotinin is favorable for high-risk patients but
not so for low-risk patients. You had these data, and I think this
would make an additional excellent analysis, and I would like to
hear your comments on that.
Dr Backer. We did try to look at risk stratification based on
Aristotle scores. We were particularly interested in the group of
patients who required postoperative temporary dialysis because
those were the patients who clearly had substantial kidney failure.
The mean Aristotle score in the no-aprotinin group that required
dialysis was 7.67. All of these patients had difficult operations,
such as tricuspid valve replacement after heart transplantation and
disrupted aortic annulus with emergency operation.
The mean Aristotle score in the aprotinin group that required
dialysis was 10.08, a high score that was almost statistically higher
than that of the other group. If you look at this patient population,
again, all these patients were at very high risk. There was a Fontan
conversion with an Aristotle score of 12, there were 2 patients in
heart transplantation status after Fontan conversion, there was a
transplantation after a ventricular assist device, and there was a
patient with a switch with an intramural coronary artery who was
on extracorporeal membrane oxygenation. We did not have any
patient who had, for example, a straightforward ventricular septal
defect closure and then had kidney failure.
The other part of the data to look at is the multivariate analysis
of biochemical acute kidney failure. The mean Aristotle score in
the group without acute kidney failure was 7.5, and in those with
acute kidney failure, it was 8.5. The Aristotle score only trended to
significance, with a P value of .063. In the patients who required
postoperative temporary dialysis, where the Aristotle score was
statistically significant (P  .001), it was 7.5 in the patients who
did not require dialysis and 9.3 in the patients who did require
postoperative dialysis.
However, your point is well taken, and we could incorporate
risk stratification as a specific subanalysis of the data.
Dr Tweddell. Those are certainly compelling data, but I would
suggest that it might be worthwhile performing the analysis.
Concerning the incidence of renal insufficiency, as determined
based on chemical data, interestingly, the preoperative creatinine
level was less in patients who sustained postoperative biochemical
renal dysfunction, at least the way you defined it. This really
causes me to question the validity of this definition. I know you
used the somewhat arbitrary definition that was developed by the
Society of Thoracic Surgeons in the multidisciplinary working
group, and the purpose of that is really to allow some multi—
institutional comparisons. Because this is a single-institution study
and because I am certain Children’s Memorial has age—specific
creatinine ranges of normalcy, you could actually analyze that
separately. I think that would be important because that is obvi-
ously an important conclusion of your article.
Dr Backer. That is a good point. We discussed with our
pediatric nephrologists what definition we should use for acute
kidney failure. One of the problems with taking the absolute value
is that if a sick patient’s preoperative creatinine level is increased,
for instance to 1.5 times normal value, then a postoperative level
of 1.5 times normal value is not a change. The Society of Thoracic
Surgeons–European Association for Cardiothoracic Surgery defi-
nition of acute kidney failure is a doubling of the creatinine level
compared with the preoperative value or a level that is 1.5 times
normal value, but the doubling seemed to take precedence for this
reason. Our pediatric nephrologists believed that using doubling of
the preoperative creatinine level as our definition would “widen
the net,” so that we would not miss patients with borderline
postoperative kidney failure.
You noted, as we did in the article, that in the multivariate
analysis there was the counterintuitive finding that the preoperative
creatinine level was 0.51 mg/dL in the patients who did not have
acute kidney failure, and it was 0.39 mg/dL in the patients who did
have acute kidney failure. The question here is whether a creati-
nine level of 0.5 versus 0.4 mg/dL is actually clinically relevant.
In contrast, for those patients who required postoperative tem-
porary dialysis, the association of preoperative creatinine level was
significant, with a P value of .03. The patients who did not require
temporary dialysis had a mean preoperative creatinine level of 0.5
mg/dL. If they did require temporary dialysis, the mean preoper-
ative value was 0.9 mg/dL. Therefore in the subgroup with kidney
failure requiring postoperative dialysis, they did have a higher
preoperative creatinine level, almost twice as high as before the
operation.
Dr Tweddell. I guess I was suggesting that you use the most
inclusive definition because that is important to rule it out. Also, I
think that is more important than the application of dialysis be-
cause that is really measuring a clinical response and not neces-
sarily biochemical evidence of renal failure.
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I have just a couple of other questions. Aprotinin is a strong
inhibitor of bradykinin generation. Bradykinin is implicated in
perioperative neurologic injury. Did you look at neurologic com-
plications, seizures, and new deficits?
Dr Backer. We do have neurologic data in our database,
although we did not specifically look at it. We could go back and
analyze that relatively easily. However, we do not currently have
late follow-up on neurologic outcomes.
Dr Tweddell. Have you had incidents of anaphylaxis, and how
do you re-expose? Do you re-expose patients within a year?
Dr Backer. We relied on your article in Circulation that
suggested that it was safe to redose aprotinin. The main group
undergoing re-exposure within a year consisted of those who had
the Norwood procedure with aprotinin and then within 4 to 6
months had the bidirectional Glenn procedure. Initially, our anes-
thesiologists were hesitant to use aprotinin during the Glenn pro-
cedure. Your article came out with the less than 1% anaphylaxis,
and therefore currently, we administer aprotinin at the Norwood
and Glenn procedures, irrespective of whether they have their
Glenn procedure at 3.5, 4, or 6 months, and again at the Fontan
procedure.
Our primary safety protocol is that every patient gets a test dose
of aprotinin, and we wait to do that until the arterial line and the
central line are in. We have had one patient who had significant
hypotension related to the aprotinin—just one patient out of this
entire group.
Dr Tweddell. Obviously there are no indications for aprotinin
use in pediatrics, but there is now a black box warning about
re-exposure within a year.
Dr Backer. Yes.
Dr Tweddell. It is one thing to use it when there is not an
indication, and it is another thing to use it against a black box
warning. I wonder if you have changed your policy at all? I think
we are struggling with that as well.
Dr Backer. We have not changed our policy. The Friday
before I came here, I did a reoperation to do a shunt revision on a
patient after the Norwood procedure. We had used aprotinin 10
days earlier, and I used aprotinin again, and nothing happened.
Granted, it is only 1 patient.
Dr Tweddell. My last and final question is whether you think
we need a postmarket randomized controlled trial in pediatrics to
approve efficacy and safety?
Dr Backer. Well, I think in an ideal world that would be a good
thing. I think if there are enough questions about this and if centers
are unable to use aprotinin because of the negative press and
because of parental concerns, a randomized prospective study
might be the only way we are going to prove its safety. There have
been several studies that have showed efficacy, and we could look
at efficacy and safety in the prospective trial. Specifically, we
could look at kidney function and even do some more in-depth
analysis, such as postoperative GFR and postoperative urine col-
lections for creatinine clearance.
Dr Tweddell. Thank you. Excellent article.
Dr Kenneth G. Warner (Boston, Mass). Did you see any
increased incidence of thrombotic complications in the aprotinin
group, such as strokes, premature closure of fenestrations, and
deep vein thrombosis?
Dr Backer. No. I mean, we have almost no thrombosis in our
patients and that was not—we did not see that.
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